grant
Core B - BWH Nanoparticle Core
Organization BETH ISRAEL DEACONESS MEDICAL CENTERLocation BOSTON, UNITED STATESPosted 1 Mar 2024Deadline 28 Feb 2029
NIHUS FederalResearch GrantFY2025AccelerationAddressAntibodiesBindingBlood VesselsBody TissuesCD3CD3 AntigensCD3 ComplexCD3 moleculeCadherinsCancer TreatmentCancersCardiovascular DiseasesCause of DeathCell BodyCellsClinicalClinical Treatment MoabColoring AgentsCore ParticleDataDevelopmentDisease remissionDoseDose LimitingDrugsDyesEncapsulatedEndocytosisEpithelial CellsEquilibriumFluorescence AgentsFluorescent AgentsFluorescent DyesGlycoproteinsGoalsGrantGuide RNAHandHigh Endothelial VenuleHomingIL-23ImmuneImmune TargetingImmune ToleranceImmune mediated therapyImmunesImmunityImmunologic ToleranceImmunologically Directed TherapyImmunosuppressantsImmunosuppressive AgentsImmunosuppressive drugImmunosuppressive treatmentImmunotherapeutic agentImmunotherapyIn VitroInfectionInflammationInflammatoryInjuryInvestigatorsInvestmentsKidneyKidney Urinary SystemKineticsL-SerineLigandsLupus Erythematosus DisseminatusLupus GlomerulonephritisLupus NephritisLymph Node Reticuloendothelial SystemLymph node properLymphatic nodesMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMediatingMedicalMedicationMedicineMetabolic DiseasesMetabolic DisorderMethodsMolecular InteractionMonoclonal AntibodiesNPHS1 gene productNanodeliveryNanotechnologyNucleosome CoreNucleosome Core ParticleOKT3 antigenOrganP01 MechanismP01 ProgramPathogenesisPathogenicityPatientsPeripheralPermeabilityPharmaceutical PreparationsProgram Project GrantProgram Research Project GrantsProtein-Serine KinaseProtein-Serine-Threonine KinasesProtein-Threonine KinasePublishingReceptor ProteinRegulatory T-LymphocyteRemissionResearch PersonnelResearch Program ProjectsResearchersSLESeriesSerineSerine KinaseSerine-Threonine KinasesSerine/Threonine Protein Kinase GeneSiteSurfaceSystemic Lupus ErythematosusSystemic Lupus ErythematousSystemic Lupus ErythmatosusT-CellsT-LymphocyteT3 AntigensT3 ComplexT3 moleculeTestingTherapeuticThesaurismosisThreonine KinaseTissuesToxic effectToxicitiesTreatment EfficacyTregTubularTubular formationUpregulationVeinsVisceral Epithelial CellWorkanti-cancer therapyantibody conjugatebalancebalance functioncancer therapycancer-directed therapycardiovascular disorderclinical effectcombinatorialdevelopmentaldisseminated lupus erythematosusdosagedrug/agentex vivo imagingexperiencefluorescent dye/probegRNAglomerular visceral epithelial cellhandsimaging in miceimaging studies for miceimaging studies in miceimmune drugsimmune suppressive agentimmune suppressorimmune system toleranceimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune unresponsivenessimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic therapeuticsimmunological paralysisimmunosuppressive substanceimmunosuppressorimmunotherapeuticsimmunotherapy agentinhibitorinjuriesinjury to tissueinnovateinnovationinnovativeinsightinterestinterleukin-23interstitialintervention efficacykidney developmentlymph glandlymph nodeslymphnodesmAbsmalignancymetabolism disordermice imagingmonoclonal Absmortalitymurine imagingnano medicinalnano medicinenano particlenano technano technologynano-sized particlenano-technologicalnanocarriernanomedicinalnanomedicinenanoparticlenanosized particlenanotechnanotechnologicalnanotherapeuticnanovesselneoplasm/cancernephrinnephrogenesisnovelpodocyteprecision medicineprecision-based medicinereceptorregulatory T-cellsrenalsite targeted deliverysystemic lupus erythematosissystemic toxicitytargeted deliverytherapeutic efficacytherapeutically effectivetherapy efficacythymus derived lymphocytetissue injurytraffickingvascularvirtual
Description preview
CORE B - ABSTRACT
Despite advancements in the development of immunosuppressive agents, the management of lupus nephritis
(LN) remains challenging. Although newer classes of immune therapeutics (ITs) have been developed, their
overall efficacy remains virtually unchanged. More intense IT regimens create serious complications, including
infection,…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click